Headache News and Research

Latest Headache News and Research

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Dengue strikes in a “vicious” way in north Qld

According to health authorities a vicious strain of Dengue fever is hospitalising people in far north Queensland. 20 people have been diagnosed with the Type 2 variant of the virus in East Innisfail and another five have Type 4 Dengue. 12 other people are possibly ill with the virus and awaiting laboratory confirmation.

15 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

Longer looks: KHN's best health policy picks from thought-provoking publications

When U.S. District Court judge Roger Vinson struck down President Obama's health care program as unconstitutional, the White House declared the decision an "outlier." It was anything but that. The ruling on January 31 was in harmony with limits the Supreme Court has imposed on the use of the Constitution's commerce clause to justify far-reaching legislation by Congress.

11 Feb 2011

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix, Inc. announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix, Inc. today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System.

9 Feb 2011

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

QLT Inc. today announced results from a Phase II proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O‑PPDS).

9 Feb 2011

Gates Foundation awards USF $5.45M for malaria research

The University of South Florida received $5.45 million in grants from the Bill & Melinda Gates Foundation. The first grant is to create advanced devices that mimic the human liver to better study the life cycle of the malaria parasite - particularly the elusive liver stage where the disease may be most vulnerable to attack.

9 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

NOCSAE warns athletes and parents not to rely solely on marketing, promotional materials

The National Operating Committee on Standards for Athletic Equipment issued a warning to athletes and parents of athletes to get the facts about football helmets and concussion protection – and not rely solely on marketing and promotional materials.

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Early, correct diagnosis is the best way to prevent the development of Lyme arthritis in individuals with the tick-borne illness, according to a paper published in the Journal of the American Academy of Orthopaedic Surgeons. In patients who do develop the condition, most cases can be treated successfully with antibiotics, the review found.

3 Feb 2011

New study reports migraine surgery eliminates headache in nearly 30% of patients

Surgery to "deactivate" migraine headaches produces lasting good results, with nearly 90 percent of patients having at least partial relief at five years' follow-up, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

2 Feb 2011

Headache News and Research

Latest Headache News and Research

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Dengue strikes in a “vicious” way in north Qld

Phase III RISE study of Lucentis for DME meets primary endpoint

Longer looks: KHN's best health policy picks from thought-provoking publications

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

Gates Foundation awards USF $5.45M for malaria research

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

NOCSAE warns athletes and parents not to rely solely on marketing, promotional materials

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

ECR launches sleep aid product, Zolpimist Oral Spray in the US

CVT more common than previously thought, disproportionally affects pregnant women

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

New study reports migraine surgery eliminates headache in nearly 30% of patients

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in